Cantor Starts Organogenesis Overweight, Cites Differentiated Portfolio (NASDAQ:ORGO)

Market rising.  Golden bull in front of laptop with stock charts.  Financial investment and trading concept.


Cantor Fitzgerald initiated coverage of Organogenesis (NASDAQ: ORGO) with an overweight rating, citing an attractive valuation and the company’s highly differentiated technology portfolio.

Cantor said he has a favorable view of the estimated $24 billion markets for advanced wound care and surgical/sports medicine. You see

Source link

Leave a Reply

Your email address will not be published. Required fields are marked *